Roche, Lilly Antibody Cocktails Threatened By Delta Plus Variant But More Evidence Needed
GSK Yet To Submit Application For Sotrovimab In India
Roche and Eli Lilly’s monoclonal antibody cocktails seem to show reduced efficacy against the Delta Plus variant, first identified in Europe, but more evidence might be needed to support the finding. Meanwhile, GSK’s Indian unit is gearing up to submit an application for accelerated approval of sotrovimab.
